2015 American Transplant Congress
A Novel Maintenance Regimen With Calcineurin Inhibitor, MMF and Everolimus Initiated By Dual Induction Therapy With Anti-CD20/25 Antibodies in Renal Transplantation
Surgery III, Tokyo Women's Medical University Hospital, Shinjuku-ku,Tokyo, Japan.
【background】Calcineurin inhibitor (CNI), MMF and steroid has been the gold standard of maintenance regimen in renal transplantation (RTx). A line of new immunosuppressants has emerged…2015 American Transplant Congress
The Relationship Between Age and Morbidity During the First Year Following Renal Transplantation in Patients Receiving Alemtuzumab Induction
Vanderbilt University Medical Center, Nashville.
BackgroundThe elderly (age ≥ 65) represent the largest growing patient population being listed for renal transplant. Immunosuppression in elderly patients presents a unique challenge, with…2015 American Transplant Congress
Long Term Outcomes With Alemtuzumab Induction Therapy for Deceased and Living Renal Transplant Recipients. A Single Center Experience
Ochsner Clinic Foundation, New Orleans, LA.
Background:Antibody induction therapy has been used for induction in up to 80% kidney transplant recipients according to United Network for Organ Sharing. It has been…2015 American Transplant Congress
A Comparison of Alemtuzumab and Antithymocyte Globulin Induction in High-Risk, Non-Sensitized African American Renal Transplant Recipients
Background:Greater than 90% of all kidney transplants(KTx) today receive an induction agent. The choice of a depleting or non-depleting agent is center specific. Alemtuzumab (Alem),…2015 American Transplant Congress
Infections After Alemtuzumab Induction: A Non Issue?
Transplant Institute, Tulane University, New Orleans, LA.
Background: Alemtuzumab is a powerful induction agent that depletes multiple lymphocyte cell lines resulting in leukopenia and/or neutropenia with concerns over infectious complications. This study…2015 American Transplant Congress
Early Use of Anti-Lymphocyte Antibody in Kidney Transplant Recipients With Delayed Graft Function Can Produce Desirable Post-Transplant Results
Department of Transplantation Surgery, Yonsei University Health System, Seoul, Republic of Korea.
Proper management of delayed graft function (DGF) is essential for successful post-transplant result in deceased donor kidney transplantation. We compared the effect of anti-lymphocyte antibody…2015 American Transplant Congress
Effect of Induction in Renal Transplant Recipients Aged 70 and Over
Transplantation, Montefiore Medical Center, Bronx, NY.
While there is a significant survival advantage to transplanting patients 70 years of age and older versus staying on dialysis, it is unclear whether sensitized…2015 American Transplant Congress
Delayed Graft Function in Patients Receiving Alemtuzumab Induction Therapy
1The University of Toledo Medical Center, Toledo, OH; 2The Alliance for Paired Donation, Maumee, OH.
Alemtuzumab (Campath 1-H) is a humanized monoclonal antibody directed at the CD52 glycoprotein that is becoming more prevalent as a choice for induction. Delayed graft…2015 American Transplant Congress
Single Center Experience With the Use of an Abbreviated Anti-Thymocyte Globulin and Basiliximab Combination Protocol in Renal Transplantation
Purpose: To report one year outcomes from single center experience with a novel induction regimen using anti-thymocyte globulin ( ATG)(rabbit)rATG (3 mg/kg) in divided doses…2015 American Transplant Congress
Clinical Consequences of Immune-Mediated Allograft Arteriosclerosis: A Population Based Study
Paris Translational Research Center for organ Transplantation, Paris, France.
BACKGROUNDThe role of circulating antibodies and alloimmune response beyond traditional cardiovascular risk factors in the development of accelerated arteriosclerosis and its long-term clinical consequences is…
American Transplant Congress abstracts